Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Mar 19, 2008
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The Retinoblastoma Survivor Study is looking to understand how surviving retinoblastoma, a type of eye cancer that usually affects children, impacts people's overall health and quality of life as adults. The study focuses on aspects like physical health, emotional well-being, and daily activities to see how these survivors feel about their lives. The goal is to gather valuable information that can help improve care for children diagnosed with retinoblastoma in the future, as well as offer better support for those who have survived it.
If you or someone you know was diagnosed with retinoblastoma at any age and has completed treatment at least five years ago, you may be eligible to participate in this study. Participants will have the chance to share their experiences and feelings about life after cancer, which could ultimately help others in similar situations. The study is open to all adults aged 65 to 74, and everyone who takes part will be asked to give their consent. This study is currently recruiting, so if you’re interested, it could be a great opportunity to contribute to important research!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient diagnosed with retinoblastoma at any age
- • At least five years from completion of all retinoblastoma-directed therapy
- • Able to provide informed consent and/or assent, if indicated
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Danielle Novetsky Friedman, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials